tyrosinase peptide

also known as tyrosinase · tyrosinase:206-214 · tyrosinase:240-251 (244S) · tyrosinase:368-376 (370D)

Developed for: cutaneous melanoma · ocular melanoma · iris melanoma · medium/large size posterior uveal melanoma · ocular melanoma with extraocular extension · melanoma · mucosal melanoma · small size posterior uveal melanoma
Investigated by: National Cancer Institute (NCI) · University of Southern California · Memorial Sloan Kettering Cancer Center · Duke University · Herbert Irving Comprehensive Cancer Center · University of Virginia

Trials 18 · a red edge is where a trial was stopped

today NCT00089063 · Ph 2 NCT00085189 · Ph 2 NCT00334776 · Ph 2 NCT00031733 · Ph 2 NCT00037037 · Ph 1 NCT00006243 · not/applicable NCT00020358 · Ph 2 NCT00005841 · Ph 1 NCT01989572 · Ph 3 NCT00005633 · Ph 1 NCT00006113 · Ph 2 NCT00003339 · Ph 2 NCT00003362 · Ph 2 NCT00003222 · Ph 2 NCT00003274 · Ph 2 NCT00019396 · Ph 2 NCT00019383 · Ph 2 NCT00003229 · Ph 1/2

1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 13 trials
Phase 1	NCT00037037	Oct 2001 → ?	cutaneous melanoma	Herbert Irving Comprehensive Cancer Center	Unknown	No outcome recorded
Phase 1	NCT00005841	Jun → Dec 2000	cutaneous melanoma, ocular melanoma	University of Southern California	Terminated	No outcome recorded
Phase 1	NCT00005633	Jun 1999 → Jun 2002	cutaneous melanoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00003229	Jul 1997 → Apr 2000	cutaneous melanoma	Duke University	Completed	No outcome recorded
Phase 212 trials
Phase 2	NCT00089063	Jun 2004 → Jun 2007	iris melanoma, medium/large size posterior uveal melanoma, ocular melanoma with extraocular extension	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00085189	May 2004 → Sep 2007	iris melanoma, medium/large size posterior uveal melanoma, mucosal melanoma, ocular melanoma with extraocular extension +1	University of Southern California	Completed	No outcome recorded
Phase 2	NCT00334776	Oct 2003 → Jun 2005	cutaneous melanoma, ocular melanoma	University of Southern California	Completed	No outcome recorded
Phase 2	NCT00031733	Feb 2002 → Dec 2004	cutaneous melanoma, ocular melanoma	University of Southern California	Completed	No outcome recorded
Phase 2	NCT00020358	Sep 2000 → Oct 2007	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00006113	Jun 1999 → May 2003	cutaneous melanoma	University of Southern California	Terminated	No outcome recorded
Phase 2	NCT00003339	Nov 1998 → Nov 1999	cutaneous melanoma, ocular melanoma	University of Southern California	Completed	No outcome recorded
Phase 2	NCT00003362	May 1998 → Feb 2001	cutaneous melanoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00003222	Apr 1998 → Sep 2003	cutaneous melanoma	University of Virginia	Completed	No outcome recorded
Phase 2	NCT00003274	Mar 1998 → Sep 2001	cutaneous melanoma	University of Southern California	Completed	No outcome recorded
Phase 2	NCT00019396	Feb 1998 → Mar 2007	melanoma, renal cell carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00019383	Jan 1998 → Jun 2003	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded

Phase 31 trial
Phase 3	NCT01989572	Feb 2000 → Oct 2012	cutaneous melanoma, iris melanoma, medium/large size posterior uveal melanoma, mucosal melanoma +2	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase not applicable1 trial
—	NCT00006243	Oct 2000 → May 2006	melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT00025181 Background	Oct 2001 → Jan 2003	cutaneous melanoma, ocular melanoma	University of Southern California	Completed	No outcome recorded
Phase 1	NCT00003665 Background	Apr 1999 → Oct 2002	cutaneous melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 21 sources stand behind the page.

Field	Value	Cited text
Known as	tyrosinase peptide	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019383 ↗ 19 NCT00005633 ↗ NCT00089063 ↗ NCT00019396 ↗ NCT00006113 ↗ NCT00006243 ↗ NCT00003229 ↗ NCT00003274 ↗ NCT00037037 ↗ NCT00003222 ↗ NCT00003339 ↗ NCT00003362 ↗ NCT00031733 ↗ NCT00334776 ↗ NCT00020358 ↗ NCT01989572 ↗ NCT00025181 ↗ NCT00003665 ↗ NCT00005841 ↗ NCT00085189 ↗
Known as	tyrosinase	“The melanoma tumor antigen epitope peptides MART-1(26-35 (27L)), gp100(209-217 (210M)),and tyrosinase(368-376 (370D)) were emulsified with incomplete Freund's adjuvant and...” PMID 12684398 ↗ Apr 2003
Known as	tyrosinase:206-214	“tyrosinase:368-376 (370D), tyrosinase:240-251 (244S), tyrosinase:206-214 (closed to accrual 11/05/01)” NCT00020358 ↗
Known as	tyrosinase:240-251 (244S)	“tyrosinase:368-376 (370D), tyrosinase:240-251 (244S), tyrosinase:206-214 (closed to accrual 11/05/01)” NCT00020358 ↗
Known as	tyrosinase:368-376 (370D)	“tyrosinase:368-376 (370D), tyrosinase:240-251 (244S), tyrosinase:206-214 (closed to accrual 11/05/01)” NCT00020358 ↗
Action	Deplete	“Vaccines made from peptides may make the body build an immune response to kill tumor cells.” NCT00089063 ↗
Modality	Peptide	“mixture of synthetic melanoma peptides” NCT00003222 ↗
Route	Subcutaneous	“vaccine comprising tyrosinase peptide and gp100 antigen emulsified in Montanide ISA-51 (ISA-51) alone subcutaneously (SQ) once a week” NCT00003274 ↗